A Randomized, Double-blind, Multicenter, Multiple-dose Study of ALX-0171 Versus Placebo Along With Standard of Care in Japanese Infants and Young Children Hospitalized for Respiratory Syncytial Virus Lower Respiratory Tract Infection
Phase of Trial: Phase II
Latest Information Update: 24 Nov 2018
At a glance
- Drugs ALX 0171 (Primary)
- Indications Respiratory syncytial virus infections
- Focus Adverse reactions
- Sponsors Ablynx
- 15 Nov 2018 Status changed from recruiting to discontinued.
- 02 Mar 2018 According to an Ablynx media release, results from the study are expected in the second half of 2019.
- 02 Mar 2018 According to an Ablynx media release, a safety review by an independent Data Monitoring Committee will occur prior to proceeding to each higher dose of the treatment.